Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Declines By 92.1%

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 19,000 shares, a drop of 92.1% from the December 31st total of 241,700 shares. Based on an average daily volume of 325,400 shares, the short-interest ratio is currently 0.1 days. Approximately 1.3% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Aptevo Therapeutics in a research note on Monday, December 9th. They set a “sell” rating on the stock.

Aptevo Therapeutics Price Performance

APVO traded up $0.07 during trading on Thursday, hitting $4.38. The stock had a trading volume of 5,575 shares, compared to its average volume of 63,024. Aptevo Therapeutics has a twelve month low of $3.65 and a twelve month high of $399.60. The stock has a 50 day simple moving average of $85.17 and a two-hundred day simple moving average of $297.46.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.